We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

67 hedge funds and large institutions have $75.8M invested in LENZ Therapeutics in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2K | Put options by funds: $1K

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

2% more funds holding

Funds holding: 66 → 67 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.15% less ownership

Funds ownership: 7.68% → 7.53% (-0.15%)

7% less capital invested

Capital invested by funds: $81.2M → $75.8M (-$5.47M)

Holders
67
Holders Change
+1
Holders Change %
+1.52%
% of All Funds
1.06%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
22
Reduced
17
Closed
11
Calls
$2K
Puts
$1K
Net Calls
+$1K
Net Calls Change
-$2K

Top Buyers

1
NM
Newtyn Management
New York
+$1.35M
2
BlackRock
BlackRock
New York
+$235K
3
Morgan Stanley
Morgan Stanley
New York
+$184K
4
Millennium Management
Millennium Management
New York
+$147K
5
CCM
Corsair Capital Management
New York
+$114K

Top Sellers

1
Federated Hermes
Federated Hermes
Pennsylvania
-$1.06M
2
PM
Prosight Management
Texas
-$900K
3
Verition Fund Management
Verition Fund Management
Connecticut
-$596K
4
CAM
Cormorant Asset Management
Massachusetts
-$519K
5
WSL
Western Standard LLC
California
-$455K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$21.2M – – –
SB
2
Samsara BioCapital
California
$21M – – –
TCM
3
Tang Capital Management
California
$5M -$171K -9,857 -3%
BlackRock
4
BlackRock
New York
$4.48M +$235K +13,539 +6%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.43M +$12K +689 +0.3%
PM
6
Prosight Management
Texas
$3.32M -$900K -51,739 -21%
Citadel Advisors
7
Citadel Advisors
Florida
$3.08M +$94.8K +5,452 +3%
BOTOTLSJU
8
Board of Trustees of The Leland Stanford Junior University
California
$1.74M – – –
NM
9
Newtyn Management
New York
$1.35M +$1.35M +77,520 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.33M +$48.3K +2,775 +4%
State Street
11
State Street
Massachusetts
$1.08M -$11.2K -643 -1%
OMC
12
OUP Management Company
Pennsylvania
$1.01M – – –
Renaissance Technologies
13
Renaissance Technologies
New York
$656K +$50.4K +2,900 +8%
Northern Trust
14
Northern Trust
Illinois
$609K -$13.7K -788 -2%
CA
15
CHI Advisors
New York
$573K – – –
AI
16
Acuitas Investments
Washington
$485K -$17 -1 -0%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$461K – – –
PFMU
18
Privium Fund Management (UK)
United Kingdom
$453K -$178K -10,230 -27%
BCM
19
Bridgeway Capital Management
Texas
$428K +$105K +6,058 +33%
Two Sigma Investments
20
Two Sigma Investments
New York
$421K +$4.24K +244 +1%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$403K +$7.7K +443 +2%
Morgan Stanley
22
Morgan Stanley
New York
$362K +$184K +10,578 +103%
AC
23
Aldebaran Capital
Indiana
$322K – – –
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$253K -$7.72K -444 -3%
Millennium Management
25
Millennium Management
New York
$237K +$147K +8,465 +163%
1
2 3 4

LENZ Hedge Fund Activity: Q3 2023 in Review

67 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2023, worth a combined $75.8M — down 6.7% from $81.2M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LENZ positions and 11 closed out — a net gain of 1 holder — while 22 added to existing stakes and 17 trimmed.

The largest buyer was Newtyn Management, opening a new position worth an estimated $1.35M. The largest seller was Federated Hermes, exiting entirely with an estimated $1.06M sold.

  • 67 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2023, up from 66 in Q2 2023.
  • Funds reported $75.8M of LENZ Therapeutics stock for Q3 2023, down 6.7% quarter-over-quarter.
  • 12 funds opened new LENZ Therapeutics positions in Q3 2023 and 11 closed out, a net change of +1 holder.
  • The largest LENZ Therapeutics buyer in Q3 2023 was Newtyn Management, an estimated $1.35M added.
  • The largest LENZ Therapeutics seller in Q3 2023 was Federated Hermes, an estimated $1.06M sold.

Based on aggregated 13F filings for Q3 2023.